Cargando…

Glioblastoma-on-a-chip construction and therapeutic applications

Glioblastoma (GBM) is the most malignant type of primary intracranial tumor with a median overall survival of only 14 months, a very poor prognosis and a recurrence rate of 90%. It is difficult to reflect the complex structure and function of the GBM microenvironment in vivo using traditional in vit...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Zuorun, Chen, Maosong, Lian, Jiangfang, Wang, Hongcai, Ma, Jingyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368971/
https://www.ncbi.nlm.nih.gov/pubmed/37503321
http://dx.doi.org/10.3389/fonc.2023.1183059
_version_ 1785077640271495168
author Xie, Zuorun
Chen, Maosong
Lian, Jiangfang
Wang, Hongcai
Ma, Jingyun
author_facet Xie, Zuorun
Chen, Maosong
Lian, Jiangfang
Wang, Hongcai
Ma, Jingyun
author_sort Xie, Zuorun
collection PubMed
description Glioblastoma (GBM) is the most malignant type of primary intracranial tumor with a median overall survival of only 14 months, a very poor prognosis and a recurrence rate of 90%. It is difficult to reflect the complex structure and function of the GBM microenvironment in vivo using traditional in vitro models. GBM-on-a-chip platforms can integrate biological or chemical functional units of a tumor into a chip, mimicking in vivo functions of GBM cells. This technology has shown great potential for applications in personalized precision medicine and GBM immunotherapy. In recent years, there have been efforts to construct GBM-on-a-chip models based on microfluidics and bioprinting. A number of research teams have begun to use GBM-on-a-chip models for the investigation of GBM progression mechanisms, drug candidates, and therapeutic approaches. This review first briefly discusses the use of microfluidics and bioprinting technologies for GBM-on-a-chip construction. Second, we classify non-surgical treatments for GBM in pre-clinical research into three categories (chemotherapy, immunotherapy and other therapies) and focus on the use of GBM-on-a-chip in research for each category. Last, we demonstrate that organ-on-a-chip technology in therapeutic field is still in its initial stage and provide future perspectives for research directions in the field.
format Online
Article
Text
id pubmed-10368971
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103689712023-07-27 Glioblastoma-on-a-chip construction and therapeutic applications Xie, Zuorun Chen, Maosong Lian, Jiangfang Wang, Hongcai Ma, Jingyun Front Oncol Oncology Glioblastoma (GBM) is the most malignant type of primary intracranial tumor with a median overall survival of only 14 months, a very poor prognosis and a recurrence rate of 90%. It is difficult to reflect the complex structure and function of the GBM microenvironment in vivo using traditional in vitro models. GBM-on-a-chip platforms can integrate biological or chemical functional units of a tumor into a chip, mimicking in vivo functions of GBM cells. This technology has shown great potential for applications in personalized precision medicine and GBM immunotherapy. In recent years, there have been efforts to construct GBM-on-a-chip models based on microfluidics and bioprinting. A number of research teams have begun to use GBM-on-a-chip models for the investigation of GBM progression mechanisms, drug candidates, and therapeutic approaches. This review first briefly discusses the use of microfluidics and bioprinting technologies for GBM-on-a-chip construction. Second, we classify non-surgical treatments for GBM in pre-clinical research into three categories (chemotherapy, immunotherapy and other therapies) and focus on the use of GBM-on-a-chip in research for each category. Last, we demonstrate that organ-on-a-chip technology in therapeutic field is still in its initial stage and provide future perspectives for research directions in the field. Frontiers Media S.A. 2023-07-12 /pmc/articles/PMC10368971/ /pubmed/37503321 http://dx.doi.org/10.3389/fonc.2023.1183059 Text en Copyright © 2023 Xie, Chen, Lian, Wang and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Zuorun
Chen, Maosong
Lian, Jiangfang
Wang, Hongcai
Ma, Jingyun
Glioblastoma-on-a-chip construction and therapeutic applications
title Glioblastoma-on-a-chip construction and therapeutic applications
title_full Glioblastoma-on-a-chip construction and therapeutic applications
title_fullStr Glioblastoma-on-a-chip construction and therapeutic applications
title_full_unstemmed Glioblastoma-on-a-chip construction and therapeutic applications
title_short Glioblastoma-on-a-chip construction and therapeutic applications
title_sort glioblastoma-on-a-chip construction and therapeutic applications
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368971/
https://www.ncbi.nlm.nih.gov/pubmed/37503321
http://dx.doi.org/10.3389/fonc.2023.1183059
work_keys_str_mv AT xiezuorun glioblastomaonachipconstructionandtherapeuticapplications
AT chenmaosong glioblastomaonachipconstructionandtherapeuticapplications
AT lianjiangfang glioblastomaonachipconstructionandtherapeuticapplications
AT wanghongcai glioblastomaonachipconstructionandtherapeuticapplications
AT majingyun glioblastomaonachipconstructionandtherapeuticapplications